Shares of Tilray Brands (NASDAQ:TLRY) are up 6% to $4.75 Wednesday afternoon, participating in a broad bid for beaten-down speculative names. The rally doesn’t change the number that defines the year for Tilray. The stock is down 48% year to date (YTD), a figure that already includes today’s gain.
The TLRY stock bid appears tied to the Treasury Department’s announcement that it will increase buybacks of long-dated government debt “by at least double” for securities from the 10-year to 30-year sector, which pushed yields lower and lifted risk assets across the board.
Treasury Buyback News Lifts Beaten-Down Names
The 10-year Treasury yield fell 5 basis points to 4.65% and the 30-year yield declined 8 basis points to 5.2%. Lower long-end yields typically reduce the discount rates applied to speculative equities, which helps explain why Tilray shares are catching a bid alongside other small-cap laggards.
The gap between today’s move and the year-to-date figure is the story. Tilray stock has fallen far faster in 2026 than every comparable measure of the cannabis complex, so sector weakness alone doesn’t explain the drop.
The Cannabis Thesis Has Drifted
Tilray’s own news flow this week illustrates how far the business has moved from a pure cannabis story. On Tuesday, Tilray Medical welcomed prescribing guidance issued by Germany’s KBV and GKV-Spitzenverband on standardized full-spectrum extracts. Rajnish Ohri, President, International, Tilray Brands, remained confident:
The guidance represents meaningful progress and provides valuable direction for healthcare professionals navigating medical cannabis prescribing. Continued legislative clarity will help strengthen confidence in the framework and support long-term stability for patients, physicians and healthcare providers.
Also Tuesday, Tilray’s Scottish craft brewer BrewDog unveiled its 2026 Advent Calendar, a 24-day countdown priced at £51.99, with pre-orders opening September 7, 2026. A UK consumer beer product hardly moves a U.S.-listed stock on its own, yet it captures the point. Tilray now operates Cannabis, Beverage, Distribution, and Wellness segments, spans more than 40 brands in over 20 countries, and describes itself as a lifestyle and consumer packaged goods company.
The beverage platform at Tilray also includes an American craft beer portfolio and an exclusive U.S. partnership with Carlsberg. Tilray holds a 45% share of Germany’s medical cannabis oil market and reaches approximately 16,000 pharmacies and major wholesalers through CC Pharma. The drift away from the pure cannabis thesis that once carried Tilray stock is what today’s rally doesn’t resolve.
Peer Cannabis Names Trade Higher
Canopy Growth (NASDAQ:CGC) stock is up 3% to $1.02. Canopy Growth stock is down 13% year to date through Tuesday’s close, a far shallower decline than Tilray’s. The company’s portfolio includes the Storz & Bickel vaporizer business and brands such as Tweed and 7ACRES.
Aurora Cannabis (NASDAQ:ACB) stock is climbing 4% to $3.80. Aurora Cannabis stock is down 13% year to date through Tuesday’s close. The company is winding down its consumer cannabis business to focus on higher-margin global medical operations.
The Amplify Alternative Harvest ETF (NYSEARCA:MJ) is up 4% to $26.08 and is down 16% year to date through Tuesday’s close. Each of these figures sits comfortably above Tilray’s 48% YTD decline.
The MSOS ETF as Sector Context
The AdvisorShares Pure US Cannabis ETF (NYSEARCA:MSOS) trades at $4.68 and is down 4% year to date through Tuesday’s close. The fund tracks U.S. multi-state cannabis operators, a distinct group from the Canadian licensed producers named in this article, which makes MSOS useful as broader sector context rather than a proxy for these specific names.
MSOS and peer cannabis funds carry meaningful volatility, including federal and state regulatory uncertainty, small-cap concentration, and a history of severe drawdowns. Position sizing for the sector should reflect that risk profile (we put the sizing rules for exactly this kind of speculative bet in a free playbook), and traders should size accordingly.
What to Watch
Wednesday’s move for Tilray shares reflects a rate-driven bid across speculative equities. Tilray’s 47% YTD decline persists after today’s gain, and the fresh company news consists of a European prescribing guideline welcomed by Tilray and a UK beer advent calendar.
Investors may want to keep an eye on whether long-end Treasury yields continue lower into the close, since that is the mechanism lifting Tilray stock and the broader cannabis complex today. The story between now and Tilray’s next earnings report remains the gap between a diversified consumer platform and a share price that still trades like a struggling pure-play cannabis producer.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks